Johnson & Johnson - Product Pipeline Review - 2016

  • ID: 3674240
  • Company Profile
  • 423 pages
  • Global Markets Direct
  • Johnson & Johnson Services, Inc.
1 of 4
Johnson & Johnson - Product Pipeline Review - 2016

Summary

‘Johnson & Johnson - Product Pipeline Review - 2016’, provides an overview of the Johnson & Johnson’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Johnson & Johnson, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Johnson & Johnson
- The report provides overview of Johnson & Johnson including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Johnson & Johnson’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Johnson & Johnson’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Johnson & Johnson’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Johnson & Johnson
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Johnson & Johnson’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Johnson & Johnson Snapshot

Johnson & Johnson Overview

Key Information

Key Facts

Johnson & Johnson - Research and Development Overview

Key Therapeutic Areas

Johnson & Johnson - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

Johnson & Johnson - Pipeline Products Glance

Johnson & Johnson - Late Stage Pipeline Products

Johnson & Johnson - Clinical Stage Pipeline Products

Johnson & Johnson - Early Stage Pipeline Products

Johnson & Johnson - Unknown Stage Pipeline Products

Johnson & Johnson - Drug Profiles

(canagliflozin + metformin hydrochloride XR)

bedaquiline fumarate

daratumumab

ustekinumab

bortezomib

golimumab

tipifarnib

(cobicistat + darunavir + emtricitabine + tenofovir alafenamide)

(naproxen sodium + sumatriptan succinate)

abiraterone acetate

canagliflozin

esketamine hydrochloride

fulranumab

guselkumab

imetelstat sodium

infliximab

JNJ-56021927

rivaroxaban

sirukumab

tapentadol hydrochloride IR

trabectedin

JNJ-54861911

(AL-335 + odalasvir + simeprevir)

AL-335

ALS-8176

Cell Therapy for HIV-1 Infection

CNTO-3157

CNTO-6785

erdafitinib

JNJ-39393406

JNJ-40411813

JNJ-42039556

JNJ-42847922

JNJ-49095397

JNJ-53718678

JNJ-56022473

JNJ-56914845

JNJ-872

odalasvir

ORM-12741

quisinostat hydrochloride

rilpivirine

siltuximab

sovaprevir

TMC-310911

toreforant tartrate

CNTO-2476

COVA-322

telaprevir

Vaccine for Prostate Cancer

ACH-3422

AL-794

ALS-8112

CNTO-7160

EVT-100 Series

EVT-103

JNJ-18038683

JNJ-38877618

JNJ-42721458

JNJ-47910382

JNJ-49122944

JNJ-54175446

JNJ-55375515

JNJ-55920839

JNJ-56136379

JNJ-61610588

JNJ-64052781

JNJ-757

JNJ-809

NVR-3778

RV-1162

RV-1729

TOP-1288

Small Molecules for Rhinovirus Infections

Small Molecules to Inhibit Viral RNA Polymerase for RSV Infections

AL-516

CNTO-530

COVA-208

COVA-420

COVA-493

COVA-494

DiTU

flubendazole

Gene Therapy for Arteriosclerosis and Endothelial Dysfunction

JNJ-26070109

JNJ-26993135

JNJ-28307474

JNJ-28312141

JNJ-28610244

JNJ-31020028

JNJ-35815208

JNJ-375

JNJ-39729209

JNJ-39933673

JNJ-40279486

JNJ-40413269

JNJ-41477670

JNJ-42314415

JNJ-42905343

JNJ-46778212

JNJ-47965567

JNJ-5234801

JNJ-54416076

Monoclonal Antibodies to Inhibit TGF-beta 1 for Fibrosis

Monoclonal Antibody for Autoimmune Diseases

Nucleozin

Recombinant Peptides to Block Kv1.3 Channel for Autoimmune Diseases

Recombinant Protein-1 for Undisclosed Indication

Recombinant Protein-2 for Undisclosed Indication

Recombinant Proteins for Inflammatory and Autoimmune Diseases

RV-1088

S-961

Small Molecule to Inhibit Capsid Protein for Hepatitis B

Small Molecule to Inhibit Endothelial Lipase for Hypercholesterolemia

Small Molecule to Inhibit FLT3 for AML

Small Molecule to Inhibit PDE10A for Schizophrenia

Small Molecule to Inhibit Stearoyl-CoA Desaturase-1 for Obesity

Small Molecules to Antagonize P2X7 for Central Nervous System

Small Molecules to Inhibit FMS for Rheumatoid Arthritis

Stem Cell Therapy for Type 1 and Type 2 Diabetes

VE-202

ALS-2135

Cellular Immunotherapy for Solid Tumors

Drugs for Cancer

Drugs for Prostate Cancer

influenza vaccine

LCTA-949

Peptides to Inhibit Ion Channel for Chronic Pain

Recombinant Protein for Inflammatory Bowel Diseases

Small Molecule to Inhibit cccDNA for Hepatitis B

Small Molecule to Inhibit Kinase for Autoimmune Diseases

Small Molecules for Central Nervous System Disorders

Small Molecules for Hepatitis B

Small Molecules for Lymphoma

Small Molecules to Antagonize Androgen Receptor for Castration-Resistant Prostate Cancer

Small Molecules to Antagonize CCR2 for Type II Diabetes

Small Molecules to Block Cav2.2 Channel for Chronic Pain

TMC-207 Back Up

VX-353

Biologics for Undisclosed Indication

JNJ-40346527

RV-6153

Johnson & Johnson - Pipeline Analysis

Johnson & Johnson - Pipeline Products by Target

Johnson & Johnson - Pipeline Products by Route of Administration

Johnson & Johnson - Pipeline Products by Molecule Type

Johnson & Johnson - Pipeline Products by Mechanism of Action

Johnson & Johnson - Recent Pipeline Updates

Johnson & Johnson - Dormant Projects

Johnson & Johnson - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Johnson & Johnson - Company Statement

Johnson & Johnson - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Johnson & Johnson, Key Information

Johnson & Johnson, Key Facts

Johnson & Johnson - Pipeline by Indication, 2016

Johnson & Johnson - Pipeline by Stage of Development, 2016

Johnson & Johnson - Monotherapy Products in Pipeline, 2016

Johnson & Johnson - Combination Treatment Modalities in Pipeline, 2016

Johnson & Johnson - Partnered Products in Pipeline, 2016

Johnson & Johnson - Partnered Products/ Combination Treatment Modalities, 2016

Johnson & Johnson - Out-Licensed Products in Pipeline, 2016

Johnson & Johnson - Out-Licensed Products/ Combination Treatment Modalities, 2016

Johnson & Johnson - Pre-Registration, 2016

Johnson & Johnson - Filing rejected/Withdrawn, 2016

Johnson & Johnson - Phase III, 2016

Johnson & Johnson - Phase II, 2016

Johnson & Johnson - Phase I, 2016

Johnson & Johnson - IND/CTA Filed, 2016

Johnson & Johnson - Preclinical, 2016

Johnson & Johnson - Discovery, 2016

Johnson & Johnson - Unknown, 2016

Johnson & Johnson - Pipeline by Target, 2016

Johnson & Johnson - Pipeline by Route of Administration, 2016

Johnson & Johnson - Pipeline by Molecule Type, 2016

Johnson & Johnson - Pipeline Products by Mechanism of Action, 2016

Johnson & Johnson - Recent Pipeline Updates, 2016

Johnson & Johnson - Dormant Developmental Projects,2016

Johnson & Johnson - Discontinued Pipeline Products, 2016

Johnson & Johnson, Subsidiaries

List of Figures

Johnson & Johnson - Pipeline by Top 10 Indication, 2016

Johnson & Johnson - Pipeline by Stage of Development, 2016

Johnson & Johnson - Monotherapy Products in Pipeline, 2016

Johnson & Johnson - Combination Treatment Modalities in Pipeline, 2016

Johnson & Johnson - Partnered Products in Pipeline, 2016

Johnson & Johnson - Out-Licensed Products in Pipeline, 2016

Johnson & Johnson - Pipeline by Top 10 Target, 2016

Johnson & Johnson - Pipeline by Top 10 Route of Administration, 2016

Johnson & Johnson - Pipeline by Top 10 Molecule Type, 2016

Johnson & Johnson - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll